Gynecologic oncology
Gynecologic oncology
Audio Summaries
Every issue of Gynecologic oncology moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from Gynecologic oncology.
Glucagon-like peptide-1 receptor agonist use and overall survival in endometrial cancer: a multicenter propensity score-matched cohort study.
Nov 17, 2026
This retrospective TriNetX cohort study asked whether GLP-1 receptor agonist use is associated with lower 5-year all-cause mortality in women with endometrial cancer. After propensity score matching and a 2-year landmark analysis anchored to diagnosis date, GLP-1RA users showed no significant survival benefit compared with non-users (primary HR 0.81, 95% CI 0.65-1.02; landmark HR 0.92, 95% CI 0.63-1.34), and results held against DPP-4 inhibitor users. The apparent protective effect (HR 0.58) seen when comparing against women who never used GLP-1RAs disappeared once follow-up was anchored to diagnosis, suggesting the earlier association may reflect study design bias rather than a true effect.
First-cycle β-hCG dynamics predict single-agent chemoresistance in low-risk gestational trophoblastic neoplasia.
Nov 14, 2026
This retrospective study of 299 low-risk gestational trophoblastic neoplasia patients asked whether the ratio of β-hCG levels before cycle 2 to before cycle 1 (C2/C1) can predict resistance to first-line single-agent chemotherapy. Using a threshold of 0.38, a first-cycle dynamic model incorporating this ratio outperformed a baseline clinical model in both development and internal validation cohorts (AUCs 0.867 and 0.844), with chemoresistance rates of roughly 44% in poor responders versus about 9% in favorable responders. Although the findings suggest the marker could help identify patients needing closer monitoring, prospective multicenter validation is still required.
"Turn that down a few notches": A qualitative analysis of uncertainty and psychosocial burden among non-BRCA previvors.
Nov 13, 2026
This qualitative study examined how non-BRCA previvors (individuals carrying variants such as Lynch-related, PALB2, RAD51C, BRIP1, or CHEK2 mutations) experience family planning, relationships, and the psychosocial burden of carrying a cancer-risk variant without a clear guideline pathway. Through semi-structured interviews with 21 previvors, the authors found that concerns about fertility and ART costs, early menopause, mutation transmission, relationship strain, and frustration over ambiguous data all shaped distress, and that lower penetrance did not reduce this burden. The authors conclude that physicians should acknowledge these uncertainties and engage in shared decision-making to better align medical recommendations with patients' personal goals.
Exploratory biomarker analysis of ribociclib plus letrozole in recurrent low-grade serous carcinoma: A GOG-3026 correlative study.
Nov 13, 2026
This exploratory translational study of the GOG-3026 trial asked which molecular and immune biomarkers (Ki-67, p16, pRB, ER/PR, genomic alterations, and immune phenotypes) are associated with response to ribociclib plus letrozole in recurrent low-grade serous ovarian carcinoma. In 24 archival tumors, lower Ki-67 was significantly associated with clinical benefit, and higher p16 showed a non-significant trend toward shorter progression-free survival, while no partial responders had an immune-hot phenotype. Because the analysis was exploratory and unadjusted for multiple testing, the authors conclude that these biomarkers warrant prospective validation before use in patient selection.
Translational science in modern gynecologic oncology trials.
Nov 12, 2026
This review provides an operational framework for building translational science into gynecologic oncology trials from the start, rather than planning biomarker endpoints late. The authors define exploratory, integrated, and integral biomarker tiers linked to analytical validation, clinical validation, and level of evidence, and propose minimum standards for tissue and blood specimen collection, handling, clinical annotation, and reporting (BRISQ, SPREC, BloodPAC). It also addresses how ctDNA and emerging platforms should be used and argues that discovery findings should not be treated as validated biomarkers.
Racial and ethnic differences in ovarian cancer survival across SEER registry states.
Nov 12, 2026
This study used SEER 17 data (2000–2022) on 103,554 ovarian, fallopian tube, and primary peritoneal cancer cases to determine whether racial and ethnic differences in ovarian cancer-specific survival vary across SEER registry states and by prognostic factors. Hispanic patients had survival similar to NH White patients, NH Asian patients had better survival, and NH Black and NH Native Hawaiian/Pacific Islander patients had worse survival, with these patterns largely consistent across states (Kentucky and Iowa being exceptions for NH Black patients). The authors conclude that the persistent, geographically consistent disparities point to broad, multi-level determinants rather than state-specific causes, supporting the need for national efforts to ensure equitable access to high-quality care.
BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer.
Nov 11, 2026
This paper describes the design of the BEHOLD Phase 3 program, which tests mocertatug rezetecan (Mo-Rez), a B7-H4-targeting antibody-drug conjugate, across five randomized studies in ovarian and endometrial cancer involving about 3,070 patients. The authors aim to determine whether Mo-Rez, which showed promising Phase 1 response rates (62% in platinum-resistant ovarian cancer and 67% in endometrial cancer), improves PFS and/or OS compared with standard care across treatment settings including replacement of chemotherapy, combinations with bevacizumab or immune checkpoint inhibitors, and maintenance therapy. The program also uses prospective tumor collection to assess whether B7-H4 expression and other biomarkers predict clinical benefit.
Time to treatment initiation in cervical cancer in the United States: Trends by treatment modality and factors associated with delay.
Nov 10, 2026
This National Cancer Database study examined how long U.S. women with cervical cancer waited from diagnosis to first treatment between 2004 and 2022, and what factors predicted longer waits. Median time to treatment rose by roughly 46-66% across radiation, surgery, and chemotherapy pathways, with longer delays linked to Medicaid or uninsured status, Hispanic ethnicity, lower neighborhood education, and diagnosis and treatment occurring at different facilities. Longer initiation was not associated with radiation extending beyond 56 days, leaving the clinical harm of these delays still unclear.
Surgical management of cervical cancer: A Society of Gynecologic Oncology evidence-based review.
Nov 10, 2026
This Society of Gynecologic Oncology evidence-based review asks how upfront surgery for cervical cancer should be managed in light of recent randomized and prospective data, covering the extent of resection, fertility-sparing options, nodal assessment, surgical approach, and integration with chemoradiation. Using a systematic literature review and a graded two-part rating system, the panel recommends simple hysterectomy with nodal assessment for low-risk stage IA–IB1 disease, fertility-sparing conization or simple trachelectomy for selected low-risk IA1–IB1 patients, and sentinel lymph node biopsy (with indocyanine green mapping) as an acceptable replacement for complete pelvic lymphadenectomy when an accepted algorithm is followed. The authors also favor an open approach for radical hysterectomy outside of trials and advise against neoadjuvant chemotherapy in place of chemoradiation or routine hysterectomy after definitive chemoradiation without residual disease, while noting that evidence quality varies and several recommendations rely on observational data or expert consensus.
National cancer database analysis of uterine carcinosarcoma: An updated series in locally advanced stage patients.
Nov 10, 2026
This National Cancer Database study asked whether the sequencing of adjuvant chemotherapy and radiation affects overall survival in surgically treated, locally advanced (FIGO stage III-IVA) uterine carcinosarcoma. Among 4,593 patients, sequential chemoradiation (separated by more than 14 days) was associated with better overall survival than chemotherapy alone (adjusted HR 0.70), whereas concurrent chemoradiation (starts within 14 days) was not (HR 1.12), and this benefit persisted across multiple sensitivity analyses. The authors conclude that sequential chemoradiation may be preferable to concurrent approaches in this setting and call for prospective trials to confirm these findings.
